Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Sherris

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Angiogenesis|March 21, 2007
Ocular drug development--future directionsDavid Sherris
Journal of Ophthalmology|December 2, 2011
Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic RetinopathyJorge L Jacot, David Sherris
Facial Plastic Surgery & Aesthetic Medicine|May 2, 2026
Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial ChangesAriel Harsinay, Mattie Rosi-Schumacher, Nicole Favre, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 22, 2011
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenatesFan Lin, David Sherris, Jos H Beijnen, et al.
Biomed Research International|September 13, 2014
Advances in prostate cancer research and treatmentLorenzo Livi, Andrea M Isidori, David Sherris, et al.
Molecules (Basel, Switzerland)|July 5, 2018
Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1Ming He, Qianyi Yang, Allison B Norvil, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 22, 2026
Nationwide Adherence to Bell's Palsy Clinical Practice Guidelines: Retrospective Analysis Using a Large-Scale EHR DatabaseNicole Favre, Ariel Harsinay, Mattie Rosi-Schumacher, et al.
International Journal of Cancer|February 26, 2013
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2Fan Lin, Levi Buil, David Sherris, et al.
Cancer Research|November 18, 2008
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeabilityQi Xue, Benjamin Hopkins, Carole Perruzzi, et al.
Journal of Cellular Biochemistry|January 13, 2017
The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast DifferentiationKeith T Ferguson, Elizabeth E Torr, Ksenija Bernau, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Angiogenesis|March 21, 2007
Ocular drug development--future directionsDavid Sherris
Journal of Ophthalmology|December 2, 2011
Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic RetinopathyJorge L Jacot, David Sherris
Facial Plastic Surgery & Aesthetic Medicine|May 2, 2026
Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial ChangesAriel Harsinay, Mattie Rosi-Schumacher, Nicole Favre, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 22, 2011
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenatesFan Lin, David Sherris, Jos H Beijnen, et al.
Biomed Research International|September 13, 2014
Advances in prostate cancer research and treatmentLorenzo Livi, Andrea M Isidori, David Sherris, et al.
Molecules (Basel, Switzerland)|July 5, 2018
Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1Ming He, Qianyi Yang, Allison B Norvil, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 22, 2026
Nationwide Adherence to Bell's Palsy Clinical Practice Guidelines: Retrospective Analysis Using a Large-Scale EHR DatabaseNicole Favre, Ariel Harsinay, Mattie Rosi-Schumacher, et al.
International Journal of Cancer|February 26, 2013
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2Fan Lin, Levi Buil, David Sherris, et al.
Cancer Research|November 18, 2008
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeabilityQi Xue, Benjamin Hopkins, Carole Perruzzi, et al.
Journal of Cellular Biochemistry|January 13, 2017
The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast DifferentiationKeith T Ferguson, Elizabeth E Torr, Ksenija Bernau, et al.
Pageof 2